191 related articles for article (PubMed ID: 34124390)
1. Success rate of microsatellite instability examination and complete response with pembrolizumab in biliary tract cancer.
Kai Y; Ikezawa K; Takada R; Daiku K; Maeda S; Abe Y; Yamai T; Fukutake N; Nakabori T; Uehara H; Nagata S; Wada H; Ohkawa K
JGH Open; 2021 Jun; 5(6):712-716. PubMed ID: 34124390
[TBL] [Abstract][Full Text] [Related]
2. Low prevalence of biliary tract cancer with defective mismatch repair genes in a Japanese hospital-based population.
Ando Y; Kumamoto K; Matsukawa H; Ishikawa R; Suto H; Oshima M; Kamada H; Morishita A; Kobara H; Matsunaga T; Haba R; Masaki T; Suzuki Y; Okano K
Oncol Lett; 2022 Jan; 23(1):4. PubMed ID: 34820003
[TBL] [Abstract][Full Text] [Related]
3. Microsatellite Instability-high Intrahepatic Cholangiocarcinoma with Portal Vein Tumor Thrombosis Successfully Treated with Pembrolizumab.
Naganuma A; Sakuda T; Murakami T; Aihara K; Watanuki Y; Suzuki Y; Shibasaki E; Masuda T; Uehara S; Yasuoka H; Hoshino T; Kudo T; Ishihara H; Ogawa T; Kitamoto Y; Ogawa A
Intern Med; 2020 Sep; 59(18):2261-2267. PubMed ID: 32536644
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of pembrolizumab in microsatellite instability-high locally advanced cholangiocarcinoma: a case report.
Toshida K; Itoh S; Yoshizumi T; Shimagaki T; Wang H; Kurihara T; Toshima T; Nagao Y; Harada N; Oki E; Nakamura Y; Yoshino T; Mori M
Clin J Gastroenterol; 2021 Oct; 14(5):1459-1463. PubMed ID: 34085164
[TBL] [Abstract][Full Text] [Related]
5. Microsatellite instability in patients with hepato-biliary-pancreatic malignancies in clinical practice (KHBO 1903).
Kubo S; Nagano H; Tsujie M; Seo S; Gotoh K; Wada H; Nakashima S; Ioka T
Int J Clin Oncol; 2022 Aug; 27(8):1340-1347. PubMed ID: 35718824
[TBL] [Abstract][Full Text] [Related]
6. Discordant microsatellite instability findings in two samples from a patient with biliary cancer that responded to pembrolizumab.
Matsubayashi H; Todaka A; Ishiwatari H; Sato J; Niiya F; Kondo T; Ono H; Yamazaki K; Sasaki K; Kiyozumi Y
Clin J Gastroenterol; 2023 Oct; 16(5):748-754. PubMed ID: 37490248
[TBL] [Abstract][Full Text] [Related]
7. Clinical features of biliary tract cancer in Japanese individuals with Lynch syndrome.
Kanaya N; Aoki H; Morito T; Taniguchi F; Shigeyasu K; Tamura C; Sugano K; Akagi K; Ishida H; Tanakaya K
J Gastrointest Oncol; 2022 Oct; 13(5):2532-2538. PubMed ID: 36388648
[TBL] [Abstract][Full Text] [Related]
8. A multicenter comparative study of endoscopic ultrasound-guided fine-needle biopsy using a Franseen needle versus conventional endoscopic ultrasound-guided fine-needle aspiration to evaluate microsatellite instability in patients with unresectable pancreatic cancer.
Takagi T; Sugimoto M; Imamura H; Takahata Y; Nakajima Y; Suzuki R; Konno N; Asama H; Sato Y; Irie H; Nakamura J; Takasumi M; Hashimoto M; Kato T; Kobashi R; Hashimoto Y; Shibukawa G; Marubashi S; Hikichi T; Ohira H
Clin Endosc; 2023 Jan; 56(1):107-113. PubMed ID: 36646425
[TBL] [Abstract][Full Text] [Related]
9. Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab.
Kawaoka T; Ando Y; Yamauchi M; Suehiro Y; Yamaoka K; Kosaka Y; Fuji Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Ono A; Murakami E; Takahashi S; Tsuge M; Hiramatsu A; Imamura M; Chayama K; Aikata H
Hepatol Res; 2020 Jul; 50(7):885-888. PubMed ID: 32088930
[TBL] [Abstract][Full Text] [Related]
10. [Clinical Outcome of Microsatellite Instability-High Patients Treated with Pembrolizumab and Genetic Counseling].
Shimura S; Tsumura H; Araki N; Kawada R; Shimazu S; Waraya M; Yoshida T; Takada F; Iwamura M; Sasaki J
Gan To Kagaku Ryoho; 2022 Oct; 49(10):1099-1104. PubMed ID: 36281602
[TBL] [Abstract][Full Text] [Related]
11. Molecular profile of BRCA-mutated biliary tract cancers.
Spizzo G; Puccini A; Xiu J; Goldberg RM; Grothey A; Shields AF; Arora SP; Khushman M; Salem ME; Battaglin F; Baca Y; El-Deiry WS; Philip PA; Nassem M; Hall M; Marshall JL; Kocher F; Amann A; Wolf D; Korn WM; Lenz HJ; Seeber A
ESMO Open; 2020 Jun; 5(3):e000682. PubMed ID: 32576609
[TBL] [Abstract][Full Text] [Related]
12. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
Kirimlioğlu H; Türkmen I; Başsüllü N; Dirican A; Karadağ N; Kirimlioğlu V
Turk J Gastroenterol; 2009 Mar; 20(1):41-7. PubMed ID: 19330734
[TBL] [Abstract][Full Text] [Related]
13. High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer.
Ahn S; Lee JC; Shin DW; Kim J; Hwang JH
Sci Rep; 2020 Jul; 10(1):12348. PubMed ID: 32704067
[TBL] [Abstract][Full Text] [Related]
14. Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.
Shen T; Zheng S; Geng L; Liu Z; Xu J; Lin B; Qian J; Zheng S
Technol Cancer Res Treat; 2020; 19():1533033820979703. PubMed ID: 33308041
[TBL] [Abstract][Full Text] [Related]
15. Conversion surgery for microsatellite instability-high gastric cancer with a complete pathological response to pembrolizumab: a case report.
Hidaka Y; Arigami T; Osako Y; Desaki R; Hamanoue M; Takao S; Kirishima M; Ohtsuka T
World J Surg Oncol; 2022 Jun; 20(1):193. PubMed ID: 35689267
[TBL] [Abstract][Full Text] [Related]
16. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA.
Barata P; Agarwal N; Nussenzveig R; Gerendash B; Jaeger E; Hatton W; Ledet E; Lewis B; Layton J; Babiker H; Bryce A; Garje R; Stein C; Kiedrowski L; Saylor P; Sartor O
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788235
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of pancreatic and biliary tract cancers in Lynch syndrome: A retrospective analysis from the Finnish National Lynch Syndrome Research Registry.
Zalevskaja K; Mecklin JP; Seppälä TT
Front Oncol; 2023; 13():1123901. PubMed ID: 36816932
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.
Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D
J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650
[TBL] [Abstract][Full Text] [Related]
19. Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability.
Ando Y; Yamauchi M; Suehiro Y; Yamaoka K; Kosaka Y; Fuji Y; Uchikawa S; Kodama K; Morio K; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Takahashi S; Tsuge M; Hiramatsu A; Imamura M; Chayama K; Aikata H
Clin J Gastroenterol; 2020 Oct; 13(5):867-872. PubMed ID: 32020539
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
Barrington DA; Dilley SE; Smith HJ; Straughn JM
Gynecol Oncol; 2019 May; 153(2):381-384. PubMed ID: 30808517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
